• Скринінг і рання діагностика гепатоцелюлярної карциноми

Скринінг і рання діагностика гепатоцелюлярної карциноми

HEALTH OF WOMAN. 2018.3(129):70–76; doi 10.15574/HW.2018.129.70

Кірієнко В. Т. , Зайцев І. А. , Грушкевич В. В. , Потій В. В.
Київський національний медичний університет імені О.О. Богомольця
Національний військово-медичний клінічний центр, Головний військовий клінічний госпіталь, м.Київ
Донецький національний медичний університет ім. М. Горького, м Лиман

У статті представлені фактори ризику розвитку гепатоцелюлярної карциноми (ГЦК), сучасні положення про можливості скринінгу і ранньої діагностики ГЦК з використанням променевих методів візуалізації, неінвазивних серологічних маркерів. Визначено категорії пацієнтів, що підлягають скринінгу ГЦК, і алгоритм обстеження.
Ключові слова: гепатоцелюлярна карцинома, первинний рак печінки, скринінг, рання діагностика.

СПИСОК ЛІТЕРАТУРИ

1. Siegel R. et al. 2014. Cancer statistics. CA. Cancer J. Clin. 64(1): 9–29. https://doi.org/10.3322/caac.21208; PMid:24399786

2. Ferlay J. et al. 2015. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN2012. Int.J. Cancer. 136(5): E359-E386. https://doi.org/10.1002/ijc.29210; PMid:25220842

3. Tejeda-Maldonado J., García-Juárez I. et al. 2015. Diagnosis and treatment of hepatocellular carcinoma. World J. Hepatol. №7: 362–376. https://doi.org/10.4254/wjh.v7.i3.362; PMid:25848464 PMCid:PMC4381163

4. El-Serag H. B., Kanwal F. 2014. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 60: 1767–1775. https://doi.org/10.1002/hep.27222; PMid:24839253 PMCid:PMC4211957

5. Федоренко З.П., Михайлович Ю.Й., Гулак Л.О. та ін. (2016) Рак в Україні, 2014–2015. Бюл. Нац. канцер-реєстру України. № 17: 144.

6. Sunkara V, Hebert JR. 2016. The application of the mortality-to-incidence ratio for the evaluation of cancer care disparities globally. Cancer . 122:487–488. https://doi.org/10.1002/cncr.29746; PMid:26484652

7. Sunkara V, Hebert JR. 2015. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. Cancer. 121:1563–1569. https://doi.org/10.1002/cncr.29228; PMid:25572676 PMCid:PMC4424055

8. Chen SL, Wang SC et al. 2017. Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries. Sci Rep. 7:40003. https://doi.org/10.1038/srep40003; PMid:28051150 PMCid:PMC5209738

9. Wang SC, Sung WW et al. 2017. The gender difference and mortality-to-incidence ratio relate to health care disparities in bladder cancer: national estimates from 33 countries. Scientific reports. 7:4360. https://doi.org/10.1038/s41598-017-04083-z; PMid:28659584 PMCid:PMC5489533

10. Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 2 (8256): 1129–33. https://doi.org/10.1016/S0140-6736(81)90585-7

11. Amit G. Singal, Pillai A, Tiro A. 2014. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLOS One. 11 (4): e1001624. https://doi.org/10.1371/journal.pmed.1001624

12. Siegel R, Naishadham D, Jemal A. 2013 Cancer statistics 2013. CA Cancer J Clin. 63 (1): 11–30. https://doi.org/10.3322/caac.21166; PMid:23335087

13. EASL–EORTC. 2012. Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology vol. 56: 908–943. https://doi.org/10.1016/j.jhep.2011.12.001; PMid:22424438

14. Perz JF, Armstrong GL, Farrington LA et al. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45(4):529–38. https://doi.org/10.1016/j.jhep.2006.05.013; PMid:16879891

15. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 118(12):3030–44. https://doi.org/10.1002/ijc.21731; PMid:16404738

16. Rosenthal E., Poiree M., Pradier C. et al. 2003. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 17:1803–1809. https://doi.org/10.1097/00002030-200308150-00009; PMid:12891066

17. Perz JF, Armstrong GL, Farrington LA. et al. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45(4):529–38. https://doi.org/10.1016/j.jhep.2006.05.013; PMid:16879891

18. Liaw Y.F., Sung J.J., Chow W.C. et al. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351:1521–1531. https://doi.org/10.1056/NEJMoa033364; PMid:15470215

19. Stewart CJR, Coldewey J, Stewart IS. 2002. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol.55:93-97. https://doi.org/10.1136/jcp.55.2.93; PMid:11865001 PMCid:PMC1769583

20. Arguedas M.R., Chen V.K. et al. 2003. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis // Am. J. Gastroenterol. 98: 679–690. https://doi.org/10.1111/j.1572-0241.2003.07327.x

21. Hashem B., El-Serag H.B. 2007. Epidemiology of hepatitis C-related hepatocellular carcinoma. Medscape. Medscape Gastroenterology. http: //www.medscape.com/viewarticle/560012.

22. Bosch FX, Ribes J, Borras J. 1999. Epidemiology of primary liver cancer. Semin Liver Dis. 19:271-285. https://doi.org/10.1055/s-2007-1007117; PMid:10518307

23. Bruix J, Sherman M. 2005. Management of hepatocellular carcinoma. Hepatology. 42:1208-1236. https://doi.org/10.1002/hep.20933; PMid:16250051

24. Wörns MA, Weinmann A. et al. 2009. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 43(5): 489–95. https://doi.org/10.1097/MCG.0b013e31818ddfc6; PMid:19247201

25. Yoshida H, Shiratori Y, Moriyama M et al. 1999. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med.131(3): 174–81. https://doi.org/10.7326/0003-4819-131-3-199908030-00003; PMid:10428733

26. Morgan RL, Baack B, Smith BD et al. 2013. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med.158 (5Pt1): 329–37. https://doi.org/10.7326/0003-4819-158-5-201303050-00005; PMid:23460056

27. Levy I., Greig P.D., Gallinger S. et al. 2001. Resection of hepatocellular carcinoma without preoperative tumor biopsy // Ann. Surg. 234: 206–209. https://doi.org/10.1097/00000658-200108000-00010; PMid:11505066 PMCid:PMC1422007

28. Gurusamy KS, Wilson R, Koretz RL et al. 2013. Is Sustained Virological Response a Marker of Treatment Efficacy in Patients with Chronic Hepatitis C Viral Infection with No Response or Relapse to Previous Antiviral Intervention? PLOS One. 8(12): e83313. https://doi.org/10.1371/journal.pone.0083313; PMid:24349487 PMCid:PMC3861485

29. Volk ML, Marrero JA. 2008. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep 10:60-66. https://doi.org/10.1007/s11894-008-0010-2

30. Fattovich G, Stroffolini T, Zagni I, Donato F. 2004. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 127 (5 Suppl. 1): S35–S50. https://doi.org/10.1053/j.gastro.2004.09.014; PMid:15508101

31. Shen YC, Hsu C, Cheng CC et al. 2012. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology. 82(5): 275–89. https://doi.org/10.1159/000337293; PMid:22555181

32. Shen YC, Hsu C, Cheng CC et al. 2012. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology. 82(5): 275–89. https://doi.org/10.1159/000337293; PMid:22555181

33. Mittal S, El-Serag HB. 2013. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 47(1): S2–S6. https://doi.org/10.1097/MCG.0b013e3182872f29; PMid:23632345 PMCid:PMC3683119

34. Torres DM, Harrison SA. 2012. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma. Semin Liver Dis. 32(1): 30–38. https://doi.org/10.1055/s-0032-1306424; PMid:22418886

35. Wong R, Corley DA. 2008. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 121(6): 525–31. https://doi.org/10.1016/j.amjmed.2008.03.005; PMid:18501235

36. McGlynn KA, London WT. 2011. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 15(2):223–43. https://doi.org/10.1016/j.cld.2011.03.006

37. Bruix J, Sherman M. 2005. Management of hepatocellular carcinoma. Hepatology. 42:1208-1236. https://doi.org/10.1002/hep.20933; PMid:16250051

38. Takamatsu S, Noguchi N. et al. 2008. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology. 55:609-614. PMid:18613418

39. Blonski W., Kotlyar D. S., Forde K. A. 2010. Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol. 16: 3603–3615. https://doi.org/10.3748/wjg.v16.i29.3603; PMid:20677332 PMCid:PMC2915420

40. Fattovich G, Stroffolini T, Zagni I, Donato F. 2004. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 127(5 Suppl 1): S35-S50. https://doi.org/10.1053/j.gastro.2004.09.014; PMid:15508101

41. Manns MP, Czaja AJ, Gorham JD, et al. 2010. Diagnosis and management of autoimmune hepatitis. Hepatology. 51:2193-213. https://doi.org/10.1002/hep.23584; PMid:20513004

42. Beaton MD, Adams PC. 2006. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol. 20:257-260. https://doi.org/10.1155/2006/428048

43. Bartlett DL, Di Bisceglie AM, Dawson LA. 2008. Cancer of the liver. In: DeVita J, V.T., Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed: Wolters Kluwer; Lippincott Williams & Wilkins.11291156.

44. Song do S, Bae SH. 2012. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol.18:258–267. https://doi.org/10.3350/cmh.2012.18.3.258; PMid:23091805 PMCid:PMC3467428

45. Davenport MS, Khalatbari S, Liu PS, et al. 2014. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology. 272:132–142. https://doi.org/10.1148/radiol.14131963; PMid:24555636 PMCid:PMC4263627

46. Bruix J, Sherman M. 2011. American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022. https://doi.org/10.1002/hep.24199; PMid:21374666 PMCid:PMC3084991

47. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. 2012. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 56: 908–43. https://doi.org/10.1016/j.jhep.2011.12.001; PMid:22424438

48. Hina Arif-Tiwari, Bobby Kalb, Surya Chundru et al. 2014. MRI of hepatocellular carcinoma: an update of current practices Diagn Interv Radiol. 20: 209–21. https://doi.org/10.5152/dir.2014.13370; PMid:24808419 PMCid:PMC4463351

49. Singal AG, Conjeevaram HS, Volk ML et al. 2012. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 21: 793–9. https://doi.org/10.1158/1055-9965.EPI-11-1005; PMid:22374994 PMCid:PMC5640437

50. Digumarthy SR, Sahani DV, Saini S. 2005. MRI in detection of hepatocellular carcinoma (HCC). Cancer Imaging.5: 20–4. https://doi.org/10.1102/1470-7330.2005.0005; PMid:16154814 PMCid:PMC1665242

51. Sporea I, Badea R, Popescu A et al. 2014. Contrast–Enhanced Ultrasound (CEUS) for the evaluation of focal liver lesions – a prospective multicenter study of its usefulness in clinical practice. Ultraschall Med. https://doi.org/10.11152/mu.2014.2066.161.is1rs2; PMid:24563420

52. Sporea I, Martie A, Bota S et al. 2014. Characterization of focal liver lesions using contrast enhanced ultrasound as a first line method: a large monocentric experience. J Gastrointestin Liver Dis. 23: 57–63. PMid:24689098

53. J.M. Llovet, M. 2012. DucreuxEASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol, 56: 908-943. https://doi.org/10.1016/j.jhep.2011.12.001; PMid:22424438

54. Kubota K, Ina H, Okada Y, Irie T. 2003. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci. 48:581–586. https://doi.org/10.1023/A:1022505203786; PMid:12757173

55. Trinchet JC, Chaffaut C, Bourcier V et al. 2011. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3– and 6-month periodicities. Hepatology. 54:1987–97. https://doi.org/10.1002/hep.24545; PMid:22144108

56. Sigal A, Volk ML, Waljee A et al. 2009. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 30:37–47. https://doi.org/10.1111/j.1365-2036.2009.04014.x; PMid:19392863

57. Andersson KL, Salomon JA, Goldie SJ, Chung RT. 2008. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 6:1418–24. https://doi.org/10.1016/j.cgh.2008.08.005; PMid:18848905 PMCid:PMC4340842

58. Yu NC, Chaudhari V, Raman SS et al. 2011. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 9: 161–7. https://doi.org/10.1016/j.cgh.2010.09.017; PMid:20920597

59. Lee KH, O’Malley ME, Haider MA, Hanbidge A. 2004. Triple-phase MDCT of hepatocellular carcinoma. AJR Am J Roentgenol. 182: 643–9. https://doi.org/10.2214/ajr.182.3.1820643; PMid:14975963

60. Solomon R. 2008. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol. 3: 1242–3. https://doi.org/10.2215/CJN.03470708; PMid:18701610 PMCid:PMC4571161

61. Yu MH, Kim JH, Yoon JH et al. 2014. Radiology. Small (≤1 cm) Hepatocellular Carcinoma: Diagnostic Performance and Imaging Features at Gadoxetic Acid-enhanced MR Imaging. 271(3): 748–60.

62. Bolondi L, Gaiani S, Celli N et al. 2005. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 42(1): 27–34. https://doi.org/10.1002/hep.20728; PMid:15954118

63. Levy I, Greig PD, Gallinger S et al. 2001. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg. 234 (2): 206–9. https://doi.org/10.1097/00000658-200108000-00010; PMid:11505066 PMCid:PMC1422007

64. Purysko AS, Remer EM, Coppa CP et al. 2012. LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics. 32:1977–95. https://doi.org/10.1148/rg.327125026; PMid:23150853

65. Khalili K, Kim TK, Jang HJ et al. 2011. Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol. 54:723–8. https://doi.org/10.1016/j.jhep.2010.07.025; PMid:21156219

66. Ayuso C, Rimola J, Garcia-Criado A. 2012. Imaging of HCC. Abdom Imaging. 37: 215–30. https://doi.org/10.1007/s00261-011-9794-x; PMid:21909721

67. Hina Arif-Tiwari, Bobby Kalb, Surya Chundru et al. 2014. MRI of hepatocellular carcinoma: an update of current practices Diagn Interv Radiol. 20: 209–21. https://doi.org/10.5152/dir.2014.13370; PMid:24808419 PMCid:PMC4463351

68. Becker-Weidman DJ, Kalb B, Sharma P et al. 2011. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging-comparison to prior same-center results after MR systems improvements. Radiology. 261: 824–33. https://doi.org/10.1148/radiol.11110157; PMid:21969663

69. Seale MK, Catalano OA, Saini S et al. 2009. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 29: 1725–48. https://doi.org/10.1148/rg.296095515; PMid:19959518

70. Catalano OA, Choy G, Zhu A et al. 2010. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology. 254: 154–62. https://doi.org/10.1148/radiol.09090304; PMid:20032150

71. Yan-Jie Zhao, Qiang JU, Guan-Cheng LI. 2013. Tumor markers for hepatocellular carcinoma (Review) Molecular and clinical oncology. 1: 593–8. https://doi.org/10.3892/mco.2013.119; PMid:24649215 PMCid:PMC3915636

72. Yamashita T, Forgues M, Wang W et al. 2008. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68: 1451–61. https://doi.org/10.1158/0008-5472.CAN-07-6013; PMid:18316609

73. Villanueva A, Minguez B, Forner A et al. 2010. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 61: 317–28. https://doi.org/10.1146/annurev.med.080608.100623; PMid:20059340 PMCid:PMC3677155

74. Hoshida Y, Nijman SM, Kobayashi M et al. 2009. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69: 7385–92. https://doi.org/10.1158/0008-5472.CAN-09-1089; PMid:19723656 PMCid:PMC3549578

75. Lok AS, Sterling RK, Everhart JE, et al. 2010. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 138:493-502. https://doi.org/10.1053/j.gastro.2009.10.031; PMid:19852963 PMCid:PMC2819612

76. Debruyne EN, Delanghe JR. 2008. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 385: 19–26. https://doi.org/10.1016/j.cca.2008.05.010; PMid:18538135

77. Zhang B.H., et al. 2004. J Cancer Res Clin Oncol. 130: 417–422. https://doi.org/10.1007/s00432-004-0552-0;https://doi.org/10.1007/s00432-004-0585-4; https://doi.org/10.1007/s00432-004-0613-4

78. Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. 2012. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol. 82: 116–40. https://doi.org/10.1016/j.critrevonc.2011.05.005; PMid:21680198

79. Nakamura S, Nouso K et al. 2006. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 101: 2038–43. https://doi.org/10.1111/j.1572-0241.2006.00681.x; PMid:16848811

80. Baek YH, Lee JH, Jang JS et al. 2009. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology. 56: 763–67. PMid:19621698

81. Yamamoto K, Imamura H, Matsuyama Y et al. 2010. AFP, AFP-L3, DCP and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 45: 1272–82. https://doi.org/10.1007/s00535-010-0278-5; PMid:20625772